NCT06881927 Eduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and/or Acute Respiratory Failure
| NCT ID | NCT06881927 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | University Hospital, Strasbourg, France |
| Condition | Sepsis and Septic Shock |
| Study Type | INTERVENTIONAL |
| Enrollment | 212 participants |
| Start Date | 2026-08-11 |
| Primary Completion | 2029-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 212 participants in total. It began in 2026-08-11 with a primary completion date of 2029-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Kidney transplantation is the treatment of choice for end-stage chronic kidney disease. Kidney transplantation is at the first rank of solid organ transplantation in France, with 3,376 grafts performed in 2022. Immunosuppressive therapy, required to prevent graft rejection, exposes graft recipients to complications related to decreased immunity, including opportunistic infections and neoplastic complications. After the earlt post-transplantation period, up to 10% of kidney transplant recipients will require admission to the intensive care unit (ICU). The main reasons for admission are septic shock and acute hypoxemic respiratory failure. ICU stay has a significant impact on these patients with a mortality rate reaching 40%, that remains increased even after ICU discharge. Furthermore, an impact on graft function has been demonstrated, with deterioration of graft function in 1/3 of patients, and among those, up to one in two will require resumption of renal replacement therapy (RRT). Although the occurrence of septic shock or acute respiratory failure related to an infection is more common and severe, the optimal management strategy for immunosuppressors is not defined in kidney transplant recipients admitted to the ICU in those settings. Maintain a high level of immunosuppressive therapies may hinder the recovery from the acute critical condition. Furthermore, these treatments have a narrow therapeutic index; for instance, the management of calcineurin inhibitors is challenging in the ICU due to pharmacodynamic changes associated with the acute situation (distribution volume, organ failure) and the numerous potential drug interactions that carry inherent risks of overdose. the investigators hypothesize that a reduction in the level of immunosuppressive treatments could promote recovery in kidney transplant recipients admitted to the ICU for septic shock and/or acute hypoxemic respiratory failure, without adversely affecting the risk of rejection or long-term renal prognosis.
Eligibility Criteria
Inclusion Criteria: * \- Adult patients, aged 18 years-old and over, * Kidney transplant recipients, with transplantation occurring more than 3 months prior to ICU admission * Patients admitted to the ICU in the setting of: * Septic shock (sepsis requiring vasopressor support, with or without hyperlactatemia), * And/or acute respiratory failure of presumed infectious origin (invasive or non-invasive ventilation, FiO2 greater than or equal to 50%), * Patients treated with at least an immunosuppressive bitherapy (including steroids, calcineurin inhibitors, mTOR inhibitors, azathioprine, or mycophenolate mofetil), * Patients affiliated with a social health insurance protection scheme, * Patients able of understanding the objectives and risks related to the research and providing a dated and signed informed consent. If patient is unable to consent: consent from relatives will be searched, and if absent, an emergency procedure will be process. * Women of childbearing potential, provided they have a negative blood pregnancy test on the day of the inclusion visit. Exclusion Criteria: * Minor patients, * Patients unable to consent: under legal protection measures, patients deprived of liberty, * Kidney transplant recipients treated with Belatacept due to the persistent effect of Belatacept, it is not possible to modulate this treatment in a short term period, * Patients with severe chronic graft dysfunction (glomerular filtration rate \< 20 ml/min/1.73m² according to the CKD-EPI formula in the month prior to admission), * Transplant renal recipients who have already resumed RRT (hemodialysis or peritoneal dialysis), * Multi-organ transplant recipients, * Pregnant women
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06881927 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Sepsis and Septic Shock. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06881927 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06881927 currently recruiting?
Yes, NCT06881927 is actively recruiting participants. Contact the research team at dpidric@chru-strasbourg.fr for enrollment information.
Where is the NCT06881927 trial being conducted?
This trial is being conducted at Strasbourg, France.
Who is sponsoring the NCT06881927 clinical trial?
NCT06881927 is sponsored by University Hospital, Strasbourg, France. The trial plans to enroll 212 participants.